Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.
复制标题
DOI：
10.1177/2474126420975303
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Wong RW
中科院分区：
文献类型：
--
作者：
Witkin AJ;Hahn P;Murray TG;Arevalo JF;Blinder KJ;Choudhry N;Emerson GG;Goldberg RA;Kim SJ;Pearlman J;Schneider EW;Tabandeh H;Wong RW
分析向美国视网膜专家协会（ASRS）报告的一系列与溴芦珠单抗相关的眼内炎症（IOI），无视网膜血管炎。ASRS治疗药物研究和安全性（ReST）委员会分析了brolucizumab后提交的IOI报告的临床特征。排除视网膜血管炎或接受眼内抗生素治疗的眼睛。收集了45例患者的49只眼。基线时的平均视力（VA）为20/49（范围20/20 - 5/200）。患者在最近一次brolucizumab注射后平均24天（范围3-63）出现IOI; 61%的患者在计划外访视时出现IOI，39%的患者在常规随访时出现IOI。IOI时的平均VA为20/67（范围20/20 - 3/200）。最常见的症状是飞蚊症（78%）和视力模糊（76%）。疼痛（20%）和发红（16%）不太常见; 3（6%）只眼无症状。IOI仅在18%的眼中为前部，仅在31%的眼中为后部，并且在51%的眼中为前部和后部。治疗包括67%的眼睛局部类固醇，而10%的眼睛没有接受任何治疗。末次随访时的平均VA为20/56（范围20/20 - 1/200）。3只眼（6%）失去3行或更多行，1只眼（2%）失去6行或更多行。不伴视网膜血管炎的Brolucizumab相关IOI通常延迟数周发作。通常，视力下降相对轻微。大多数症状消退，几乎所有患者的VA均恢复至基线水平，但有一小部分患者在末次随访时VA显著降低。
To analyze a series of eyes with brolucizumab-associated intraocular inflammation (IOI) without retinal vasculitis reported to the American Society of Retina Specialists (ASRS). The ASRS Research and Safety in Therapeutics (ReST) Committee analyzed clinical characteristics from submitted reports of IOI after brolucizumab. Eyes with retinal vasculitis or that received intraocular antibiotics were excluded. Forty-nine eyes of 45 patients were collected. Mean visual acuity (VA) at baseline was 20/49 (range 20/20 – 5/200). Patients presented with IOI a mean of 24 (range 3-63) days after most recent brolucizumab injection; 61% presented for an unscheduled visit while 39% presented at routine follow-up. Mean VA at IOI presentation was 20/67 (range 20/20 – 3/200). Most common symptoms were floaters (78%) and blurry vision (76%). Pain (20%) and redness (16%) were less common; 3 (6%) eyes were asymptomatic. IOI was anterior only in 18%, posterior only in 31%, and both anterior and posterior in 51% of eyes. Treatment included topical steroids alone in 67% eyes, while 10% eyes received no treatment. Mean VA at last follow-up was 20/56 (range 20/20 – 1/200). Three (6%) eyes lost 3 or more lines and 1 (2%) eye lost 6 or more lines. Brolucizumab-associated IOI without retinal vasculitis typically presented with a delayed onset of a few weeks. Often, visual acuity decline was relatively mild. Most symptoms resolved and nearly all had a return to baseline VA, but a small percentage of patients had a significant decrease in VA at last follow-up.
登录
查看更多内容
影响因子：
13.7
作者：
Dugel, Pravin U.;Koh, Adrian;Holz, Frank G.
通讯作者：
Holz, Frank G.
影响因子：
4.1
作者：
Georgopoulos, M.;Polak, K.;Schmidt-Erfurth, U.
通讯作者：
Schmidt-Erfurth, U.
影响因子：
4.2
作者：
Goldberg, Roger A.;Shah, Chirag P.;Heier, Jeffrey S.
通讯作者：
Heier, Jeffrey S.
DOI：
10.3928/23258160-20190503-05
发表时间：
2019-05-01
期刊：
Ophthalmic surgery, lasers & imaging retina
影响因子：
--
作者：
Melo, Gustavo Barreto;Figueira, Ana Carolina Migliorini;Maia, Mauricio
通讯作者：
Maia, Mauricio
影响因子：
8.1
作者：
Hahn, Paul;Chung, Mina M.;Dugel, Pravin U.
通讯作者：
Dugel, Pravin U.